These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Ma D; McDevitt MR; Finn RD; Scheinberg DA Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800 [TBL] [Abstract][Full Text] [Related]
9. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics. Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760 [TBL] [Abstract][Full Text] [Related]
10. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies. Jurcic JG Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418 [TBL] [Abstract][Full Text] [Related]
11. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Rosenblat TL; McDevitt MR; Mulford DA; Pandit-Taskar N; Divgi CR; Panageas KS; Heaney ML; Chanel S; Morgenstern A; Sgouros G; Larson SM; Scheinberg DA; Jurcic JG Clin Cancer Res; 2010 Nov; 16(21):5303-11. PubMed ID: 20858843 [TBL] [Abstract][Full Text] [Related]
12. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Morgenstern A; Bruchertseifer F; Apostolidis C Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390 [TBL] [Abstract][Full Text] [Related]
13. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533 [TBL] [Abstract][Full Text] [Related]
14. Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study. Vandenbulcke K; Thierens H; Offner F; Janssens A; de Gelder V; Bacher K; Philippé J; De Vos F; Dierckx R; Apostolidis C; Morgenstern A; Slegers G Nucl Med Commun; 2004 Nov; 25(11):1131-6. PubMed ID: 15577593 [TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy with alpha-particle emitting radionuclides. Zalutsky MR; Pozzi OR Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792 [TBL] [Abstract][Full Text] [Related]
16. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986 [TBL] [Abstract][Full Text] [Related]
17. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Ballangrud AM; Yang WH; Charlton DE; McDevitt MR; Hamacher KA; Panageas KS; Ma D; Bander NH; Scheinberg DA; Sgouros G Cancer Res; 2001 Mar; 61(5):2008-14. PubMed ID: 11280760 [TBL] [Abstract][Full Text] [Related]